Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janelle Sharkey

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Blood|October 13, 2006
PKC412 demonstrates JNK-dependent activity against human multiple myeloma cellsJanelle Sharkey, Tiffany Khong, Andrew Spencer
Haematologica|April 30, 2008
The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myelomaTiffany Khong, Janelle Sharkey, Andrew Spencer
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2009
CD1d activation and blockade: a new antitumor strategyMichele W L Teng, Simon Yue, Janelle Sharkey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2009
CD1d-based combination therapy eradicates established tumors in miceMichele W L Teng, Janelle Sharkey, Nicole M McLaughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisJohn Stagg, Upulie Divisekera, Nicole McLaughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2008
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesisJeremy B Swann, Matthew D Vesely, Anabel Silva, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2008
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseJohn Stagg, Janelle Sharkey, Sandra Pommey, et al.
Blood|February 24, 2009
Type I natural killer T cells suppress tumors caused by p53 loss in miceJeremy B Swann, Adam P Uldrich, Serani van Dommelen, et al.
Journal of Translational Medicine|April 30, 2010
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in miceJennifer A Westwood, Phillip K Darcy, Preethi Mayura Guru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in MiceJennifer A Westwood, Nicole M Haynes, Janelle Sharkey, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Blood|October 13, 2006
PKC412 demonstrates JNK-dependent activity against human multiple myeloma cellsJanelle Sharkey, Tiffany Khong, Andrew Spencer
Haematologica|April 30, 2008
The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myelomaTiffany Khong, Janelle Sharkey, Andrew Spencer
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2009
CD1d activation and blockade: a new antitumor strategyMichele W L Teng, Simon Yue, Janelle Sharkey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2009
CD1d-based combination therapy eradicates established tumors in miceMichele W L Teng, Janelle Sharkey, Nicole M McLaughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisJohn Stagg, Upulie Divisekera, Nicole McLaughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2008
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesisJeremy B Swann, Matthew D Vesely, Anabel Silva, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2008
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseJohn Stagg, Janelle Sharkey, Sandra Pommey, et al.
Blood|February 24, 2009
Type I natural killer T cells suppress tumors caused by p53 loss in miceJeremy B Swann, Adam P Uldrich, Serani van Dommelen, et al.
Journal of Translational Medicine|April 30, 2010
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in miceJennifer A Westwood, Phillip K Darcy, Preethi Mayura Guru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in MiceJennifer A Westwood, Nicole M Haynes, Janelle Sharkey, et al.
Pageof 2